The CLAHRC WM Director was awarded a grant to study uptake of effective practice in the UK over 20 years ago. The study showed that the majority of eligible patients were receiving antenatal corticosteroids in the UK. However, it would appear that this treatment, which is effective in protecting the newborn from respiratory disease and brain damage, is given to only half of eligible people across 29 low- and middle-income countries. The next step should be to identify barriers and facilitators to guide development of an intervention.
— Richard Lilford, CLAHRC WM Director
- Wilson B, Thornton JG, Hewison J, Lilford RJ, Watt I, Braunholtz D, Robinson M. The Leeds University Maternity Audit Project. Int J Qual Health Care. 2002; 14(3): 175-81.
- Vogel JP, Souza JP, Gülmezoglu AM, et al. Use of antenatal corticosteroids and tocolytic drugs in preterm births in 29 countries: an analysis of the WHO Multicountry Survey on Maternal and Newborn Health. 2014; 384(9957): 1869-77.